266 related articles for article (PubMed ID: 34511219)
1. Biology of COVID-19 and related viruses: Epidemiology, signs, symptoms, diagnosis, and treatment.
Kaye AD; Cornett EM; Brondeel KC; Lerner ZI; Knight HE; Erwin A; Charipova K; Gress KL; Urits I; Urman RD; Fox CJ; Kevil CG
Best Pract Res Clin Anaesthesiol; 2021 Oct; 35(3):269-292. PubMed ID: 34511219
[TBL] [Abstract][Full Text] [Related]
2. Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review.
Yang CJ; Wei YJ; Chang HL; Chang PY; Tsai CC; Chen YH; Hsueh PR
J Microbiol Immunol Infect; 2021 Feb; 54(1):27-36. PubMed ID: 33060041
[TBL] [Abstract][Full Text] [Related]
3. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
Atzrodt CL; Maknojia I; McCarthy RDP; Oldfield TM; Po J; Ta KTL; Stepp HE; Clements TP
FEBS J; 2020 Sep; 287(17):3633-3650. PubMed ID: 32446285
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection.
Thoguluva Chandrasekar V; Venkatesalu B; Patel HK; Spadaccini M; Manteuffel J; Ramesh M
J Med Virol; 2021 Feb; 93(2):775-785. PubMed ID: 32667699
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki K; Chakraborty A; Sur S
J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
Trials; 2020 May; 21(1):422. PubMed ID: 32448345
[TBL] [Abstract][Full Text] [Related]
7. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
8. Current perspective on diagnosis, epidemiological assessment, prevention strategies, and potential therapeutic interventions for severe acute respiratory infections caused by 2019 novel coronavirus (SARS-CoV-2).
Rizwan K; Rasheed T; Khan SA; Bilal M; Mahmood T
Hum Vaccin Immunother; 2020 Dec; 16(12):3001-3010. PubMed ID: 32881628
[TBL] [Abstract][Full Text] [Related]
9. Preferential use of dexamethasone for fetal lung maturation in severe coronavirus disease 2019.
Dellapiana G; Naqvi M; Leggett C; Tholemeier L; Burwick RM
Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100218. PubMed ID: 32844157
[No Abstract] [Full Text] [Related]
10. Corona viruses: reaching far beyond the common cold.
Coerdt KM; Khachemoune A
Afr Health Sci; 2021 Mar; 21(1):207-213. PubMed ID: 34394299
[TBL] [Abstract][Full Text] [Related]
11. Severe Acute Respiratory Syndrome Coronavirus 2 and Coronavirus Disease 2019: A Clinical Overview and Primer.
Knight TE
Biopreserv Biobank; 2020 Dec; 18(6):492-502. PubMed ID: 32726140
[TBL] [Abstract][Full Text] [Related]
12. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
13. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Andreou A; Trantza S; Filippou D; Sipsas N; Tsiodras S
In Vivo; 2020 Jun; 34(3 Suppl):1567-1588. PubMed ID: 32503814
[TBL] [Abstract][Full Text] [Related]
14. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2.
Yuan S; Yin X; Meng X; Chan JF; Ye ZW; Riva L; Pache L; Chan CC; Lai PM; Chan CC; Poon VK; Lee AC; Matsunaga N; Pu Y; Yuen CK; Cao J; Liang R; Tang K; Sheng L; Du Y; Xu W; Lau CY; Sit KY; Au WK; Wang R; Zhang YY; Tang YD; Clausen TM; Pihl J; Oh J; Sze KH; Zhang AJ; Chu H; Kok KH; Wang D; Cai XH; Esko JD; Hung IF; Li RA; Chen H; Sun H; Jin DY; Sun R; Chanda SK; Yuen KY
Nature; 2021 May; 593(7859):418-423. PubMed ID: 33727703
[TBL] [Abstract][Full Text] [Related]
15. Human and novel coronavirus infections in children: a review.
Rajapakse N; Dixit D
Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
[TBL] [Abstract][Full Text] [Related]
16. Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing.
Trkulja V
Eur J Clin Pharmacol; 2021 Jun; 77(6):935-937. PubMed ID: 33404753
[No Abstract] [Full Text] [Related]
17. The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment.
Younis NK; Zareef RO; Maktabi MAN; Mahfouz R
Genet Test Mol Biomarkers; 2021 Feb; 25(2):85-101. PubMed ID: 33596144
[TBL] [Abstract][Full Text] [Related]
18. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.
Camprubí D; Gaya A; Marcos MA; Martí-Soler H; Soriano A; Mosquera MDM; Oliver A; Santos M; Muñoz J; García-Vidal C
Int J Infect Dis; 2021 Mar; 104():379-381. PubMed ID: 33359065
[TBL] [Abstract][Full Text] [Related]
19. New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19.
Aleissa MM; Silverman EA; Paredes Acosta LM; Nutt CT; Richterman A; Marty FM
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139290
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak.
Maciorowski D; Ogaugwu C; Durvasula SR; Durvasula R; Kunamneni A
SLAS Discov; 2021 Mar; 26(3):311-329. PubMed ID: 33319627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
